MDNA Life Sciences Mitomic Prostate Test
MDNA Life Sciences has announced the UK release for its PCR-based Mitomic Prostate Test (MPT). The MPT is a liquid biopsy assay optimized for the early detection of prostate cancer in advance of biopsy. The firm designed the MPT for testing men with clinical suspicion of prostate cancer to determine their likelihood of clinically significant cancer that may benefit from rapid intervention. The test will run on MDNA's CE-IVD kit, which contains the needed reagents to process up to 21 patient samples at a time.